Prostalund AB's EBIT per Share for the
three
months ended in Sep. 2025 was €-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was €-0.50.
During the past 3 years, the average EBIT per Share Growth Rate was 62.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 57.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 38.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Prostalund AB's EBIT per Share or its related term are showing as below:
FRA:7PL0'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -50.9 Med: 22.4 Max: 68.5
Current: 62.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Prostalund AB was 68.50% per year. The lowest was -50.90% per year. And the median was 22.40% per year.
FRA:7PL0's 3-Year EBIT Growth Rate is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 11.9
vs FRA:7PL0: 62.80
Prostalund AB's EBIT for the
three
months ended in Sep. 2025 was €-0.24 Mil.
Prostalund AB (FRA:7PL0) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Prostalund AB EBIT per Share Related Terms
Prostalund AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Prostalund AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostalund AB (FRA:7PL0) has a EBIT per Share of €-0.50 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Prostalund AB and its competitors.
Is Prostalund AB's EBIT per Share too high?
Prostalund AB's current EBIT per Share is €-0.50. Overall, Prostalund AB has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Prostalund AB's EBIT per Share compare to HCA and THC?
Prostalund AB's EBIT per Share of €-0.50 can be compared against companies in the Healthcare Providers & Services industry. The industry median EBIT per Share is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.90, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Prostalund AB and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostalund AB's current EBIT per Share is €-0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostalund AB stock overvalued right now?
Prostalund AB (FRA:7PL0) has a current EBIT per Share of €-0.50. The stock's GF Value™ is €0.02, compared to a current price of €0.00 — trading 97.5% below its estimated fair value. The current EBIT per Share is €-0.50. Prostalund AB's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Prostalund AB (FRA:7PL0), the current EBIT per Share is €-0.50 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostalund AB (FRA:7PL0) Overvalued in 2026?
Based on GuruFocus' analysis, Prostalund AB stock appears to be undervalued.
The current stock price of €0.00 is trading 97.5% below its estimated GF Value™ of €0.02.
Key valuation signals for FRA:7PL0:
EBIT per Share: €-0.50
GF Value™: €0.02 vs. price of €0.00 (97.5% below fair value)
No single metric tells the full story. See the FRA:7PL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostalund AB develops, markets and sells urological products. The Company has a treatment concept (CoreTherm Concept) for personalized heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50. It has developed a new platform, CoreTherm Eagle which includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians.
10GF Score
Get the complete analysis for FRA:7PL0
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7PL0 has been successfully added to your 
